Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Information source: VA Pharmacy Benefits Management Strategic Healthcare Group
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Favor one of two thiazides for new prescriptions & attempt target dose (Other)
Phase: Phase 4
Status: Recruiting
Sponsored by: VA Pharmacy Benefits Management Strategic Healthcare Group Official(s) and/or principal investigator(s):
Madeline McCarren, PhD, MPH, Principal Investigator, Affiliation: VA Pharmacy Benefits Management
Overall contact:
Madeline McCarren, PhD, MPH, Phone: 708-786-7987, Email: madeline.mccarren@va.gov
Summary
This is a pilot study of a method to compare common, FDA-approved drugs in a clinic. Instead
of putting single patients into one of two drug groups, the investigators will assign the
doctors who prescribe these drugs for high blood pressure into two groups. One group of
doctors has agreed to prescribe mostly ("favor") one drug, chlorthalidone, if that drug
would be a good choice for a patient. The other group has agreed to prescribe mostly
hydrochlorothiazide. For both groups, they will try to use the doses that were shown to be
protective in other trials. If the doctors mostly prescribe the drug they agreed to favor,
the investigators will be able to compare outcomes, like heart attacks, in the two groups.
Clinical Details
Official title: Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Primary outcome: prescription rates
Secondary outcome: factors associated with prescribing patterns
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- VA prescribers of thiazides for hypertension
Exclusion Criteria:
- at non-participating VA sites
Locations and Contacts
Madeline McCarren, PhD, MPH, Phone: 708-786-7987, Email: madeline.mccarren@va.gov
Edward Hines, Jr. VA Hospital, Hines, Illinois 60141, United States; Not yet recruiting
Madeline McCarren, PhD, MPH, Principal Investigator
Charles George VAMC, Asheville, North Carolina 28805, United States; Recruiting
Brian Peek, PharmD, Phone: 828-298-7911, Ext: 5782, Email: Brian.Peek@va.gov
Philip Nelson, PharmD, Phone: 828-298-7911, Email: philip.nelson@va.gov
Brian Peek, PharmD, Principal Investigator
Philip Nelson, PharmD, Sub-Investigator
Wilkes-Barre VA Medical Center, Wilkes-Barre, Pennsylvania 18711, United States; Recruiting
FaizMohamed M Mansuri, MD, Email: FaizMohamed.Mansuri@va.gov
FaizMohamed M Mansuri, MD, Principal Investigator
WJB Dorn VA Medical Center, Columbia, South Carolina 29209, United States; Recruiting
Brianne Dunn, PharmD, Email: Brianne.Dunn@va.gov
Brianne Dunn, PharmD, Principal Investigator
WJB Dorn VAMC/Columbia Orangeburg VA Outpatient Clinic, Orangeburg, South Carolina 29118, United States; Recruiting
Elaine Twedt, PharmD, Email: Elaine.Twedt@va.gov
Elaine Twedt, PharmD, Principal Investigator
Additional Information
Starting date: September 2011
Last updated: September 17, 2012
|
